Eliem Therapeutics Inc (NASDAQ:ELYM) has a beta value of -0.33 and has seen 1.11 million shares traded in the last trading session. The company, currently valued at $468.75M, closed the last trade at $6.99 per share which meant it lost -$0.37 on the day or -5.03% during that session. The ELYM stock price is -65.24% off its 52-week high price of $11.55 and 66.38% above the 52-week low of $2.35. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.32 million shares traded. The 3-month trading volume is 204.21K shares.
The consensus among analysts is that Eliem Therapeutics Inc (ELYM) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Eliem Therapeutics Inc (NASDAQ:ELYM) trade information
Sporting -5.03% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ELYM stock price touched $6.99 or saw a rise of 11.41%. Year-to-date, Eliem Therapeutics Inc shares have moved 158.89%, while the 5-day performance has seen it change 16.50%. Over the past 30 days, the shares of Eliem Therapeutics Inc (NASDAQ:ELYM) have changed -11.74%. Short interest in the company has seen 1.07 million shares shorted with days to cover at 4.43.
Eliem Therapeutics Inc (ELYM) estimates and forecasts
The company’s shares have gained 159.85% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -46.72% over the past 5 years.
ELYM Dividends
Eliem Therapeutics Inc is expected to release its next earnings report in October this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Eliem Therapeutics Inc (NASDAQ:ELYM)’s Major holders
Insiders own 10.38% of the company shares, while shares held by institutions stand at 77.67% with a share float percentage of 86.66%. Investors are also buoyed by the number of investors in a company, with Eliem Therapeutics Inc having a total of 67.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 31.42 million shares worth more than $223.39 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 103.5246% of shares outstanding.
The other major institutional holder is DEEP TRACK CAPITAL, LP, with the holding of over 3.9 million shares as of 2024-06-30. The firm’s total holdings are worth over $27.76 million and represent 12.866% of shares outstanding.
